Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Lowered by Piper Sandler

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by equities researchers at Piper Sandler from an “overweight” rating to a “neutral” rating in a report released on Friday, MarketBeat reports. They currently have a $39.00 price target on the specialty pharmaceutical company’s stock. Piper Sandler’s target price would indicate a potential upside of 3.01% from the company’s previous close.

Several other equities research analysts have also commented on COLL. Needham & Company LLC reissued a “buy” rating and issued a $40.00 price target on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Truist Financial boosted their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, February 26th. Finally, StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 1st. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of “Hold” and an average price target of $39.00.

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $37.86 on Friday. The company has a debt-to-equity ratio of 2.48, a current ratio of 1.17 and a quick ratio of 1.10. The company’s fifty day moving average price is $37.63 and its 200-day moving average price is $32.21. Collegium Pharmaceutical has a 1-year low of $20.83 and a 1-year high of $40.95. The firm has a market capitalization of $1.24 billion, a PE ratio of 32.08 and a beta of 1.06.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. The firm had revenue of $149.75 million during the quarter, compared to analyst estimates of $147.66 million. On average, equities research analysts predict that Collegium Pharmaceutical will post 5.63 EPS for the current year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently modified their holdings of the business. State Board of Administration of Florida Retirement System raised its holdings in Collegium Pharmaceutical by 55.8% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,410 shares of the specialty pharmaceutical company’s stock valued at $598,000 after acquiring an additional 5,520 shares during the last quarter. ProShare Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 3.3% in the first quarter. ProShare Advisors LLC now owns 8,826 shares of the specialty pharmaceutical company’s stock valued at $343,000 after purchasing an additional 281 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Collegium Pharmaceutical by 3.2% during the first quarter. Russell Investments Group Ltd. now owns 33,084 shares of the specialty pharmaceutical company’s stock worth $1,284,000 after buying an additional 1,011 shares in the last quarter. LSV Asset Management lifted its position in Collegium Pharmaceutical by 188.7% during the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock worth $14,773,000 after buying an additional 248,751 shares in the last quarter. Finally, Gallacher Capital Management LLC acquired a new position in Collegium Pharmaceutical during the first quarter worth $223,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.